Efficacy and Safety Study of AVB-S6-500 in Patients With Platinum-Resistant Recurrent Ovarian Cancer
Public ClinicalTrials.gov record NCT03639246. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1b/2 Randomized, Controlled Study of AVB-S6-500 in Combination With Pegylated Liposomal Doxorubicin (PLD) or Paclitaxel (Pac) in Patients With Platinum-resistant Recurrent Ovarian Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase 1b/2 study of AVB-S6-500 in combination with pegylated liposomal doxorubicin (PLD) or paclitaxel (Pac) in patients with platinum resistant recurrent ovarian cancer. The phase 1b portion of the study is open label and patients will receive either AVB-S6-500+PLD or AVB-S6-500+ Pac. The Phase 2 portion of the study is randomized, double-blind, placebo-controlled study to compare efficacy and tolerability of AVB-S6-500 in combination with PLD or Pac versus placebo plus PLD or Pac.
Study identification
- NCT ID
- NCT03639246
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 53 participants
Conditions and interventions
Conditions
Interventions
- AVB-S6-500 Drug
- Paclitaxel (Pac) Drug
- Pegylated liposomal doxorubicin (PLD) Drug
- Placebo Other
Drug · Other
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 5, 2018
- Primary completion
- Jan 7, 2021
- Completion
- Dec 29, 2022
- Last update posted
- Feb 12, 2023
2018 – 2022
United States locations
- U.S. sites
- 16
- U.S. states
- 7
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Arizona Oncology | Phoenix | Arizona | 85016 | — |
| Arizona Oncology Associates | Tucson | Arizona | 85711 | — |
| Kaiser Permanente Oakland | Oakland | California | 94611 | — |
| Kaiser Permanente Roseville | Roseville | California | 95661 | — |
| Kaiser Permanente San Francisco | San Francisco | California | 94115 | — |
| Kaiser Permanente Santa Clara | Santa Clara | California | 95051 | — |
| Kaiser Permanente Vallejo | Vallejo | California | 94589 | — |
| Kaiser Permanente Walnut Creek | Walnut Creek | California | 94596 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02214 | — |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| Washington University | St Louis | Missouri | 63110 | — |
| OUHSC-Stephenson Cancer Center | Oklahoma City | Oklahoma | 73104 | — |
| Willamette Valley Cancer Institute and Research Center | Eugene | Oregon | 97401 | — |
| Texas Oncology - Austin Central | Austin | Texas | 78731 | — |
| Texas Oncology - Fort Worth | Fort Worth | Texas | 76104 | — |
| Texas Oncology - San Antonio Medical Center | San Antonio | Texas | 78240 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03639246, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 12, 2023 · Synced Sep 3, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03639246 live on ClinicalTrials.gov.